Form D · Biotechnology

INTARCIA THERAPEUTICS, INC

Boston, MA · CIK 0001086688

Offering snapshot reported Jan 14, 2020 · SEC filing

Reported sold
$198M
Offering amount: $280M
Investors reported
45
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 26, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$99.2M$198MMar 12, 2019: $73,125,000.00Mar 12, 2019Jan 14, 2020: $198,498,007.00Jan 14, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$73,125,000 → $198,498,007
  • Reported investors30 → 45

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 14, 2020Amendment$198,498,007$125,373,007vs Mar 12, 201945SEC filing
Mar 12, 2019Initial$73,125,000No comparison30SEC filing
Aug 4, 2017Amendment$524,601,480$340,241,340vs Sep 15, 201690SEC filing
Apr 3, 2017Amendment$475,676,760$84,987,480vs Jan 6, 201775SEC filing
Jan 13, 2017Initial$3,594No comparison1SEC filing
Jan 6, 2017Amendment$390,689,280$206,329,140vs Sep 15, 201638SEC filing
Sep 15, 2016Initial$184,360,140No comparison28SEC filing
Apr 7, 2014Initial$200,000,023No comparison38SEC filing
Nov 29, 2012Initial$155,897,595No comparison23SEC filing
Nov 29, 2012Initial$7,868,967No comparison15SEC filing
Nov 29, 2012Initial$698,964No comparison4SEC filing
Aug 30, 2012Amendment$45,791,354$5,485,425vs Aug 25, 201135SEC filing
Aug 22, 2012Initial$7,250,000No comparison1SEC filing
Aug 25, 2011Amendment$40,305,929$13,285,934vs Jun 10, 201134SEC filing
Jun 10, 2011Amendment$27,019,995$22,019,245vs Sep 7, 201032SEC filing
Sep 7, 2010Initial$5,000,750No comparison8SEC filing
May 14, 2010Initial$14,488,394No comparison30SEC filing
Jan 15, 2010Amendment$9,026,189$2,021,059vs Dec 2, 200933SEC filing
Dec 2, 2009Initial$7,005,130No comparison10SEC filing
Apr 30, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Apr 2, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Feb 8, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Apr 28, 2005PaperNot reportedNo comparisonNot reportedSEC filing
Dec 6, 2004PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$3M (estimated)
Finders' fees
$0
Form D file number
021-334622

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Morgan Stanley & Co. LLC8209

Source: Form D, filed Jan 14, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Ahlers Executive
Thomas Alessi Executive
Tom Alessi Executive
Michelle Baron Executive
Patrick Conway Director
Paul Feldman Executive
Fred Fiedorek Executive
David Franklin Executive
Kurt Graves Director, Executive
Owen Hughes, Jr. Executive
Anthony Hurley Executive
Raymond Keane Executive
Bob Kerrey Director
K. Alice Leung Director, Executive
Kenneth L. Luskey Executive
Ed Mathers Director
Barbara Mc Clung Executive
James Niedel Director
Emad Rizk Director
Bryan Roberts Director
Jim Rosenthal Director
Gino Santini Director
Glen Sato Director
Irwin Scher Director
Jay Skyler Director
Jay Smith Executive
David Spellman Executive
Nancy Thornberry Director
Anders Vinther Executive
Thane Wettig Executive
Michael Williams Executive
John Yee Executive
Sunita Zalani Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
One Marina Park Drive 13th Floor
Boston, MA, 02210